Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.22.1
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 1,395,112 1,078,163
Research & Development Expenses 2,629,741 1,350,976
Interest Expense & Accretion of Debt Discount 660,564
Share Based Compensation 97,000
Loss from Operations (4,121,853) (3,089,703)
Other (Income) Expenses    
Loss on Investments 1,650
Loss on Fair Market Value of Equity Investments 3,092
Interest & Dividend Income (120)
Uninsured Casualty Gain (4,442)
Total Other Expense 180
Loss Before Income Tax (4,122,033) (3,089,703)
Income Tax Benefit
Net Loss $ (4,122,033) $ (3,089,703)
Basic and Diluted loss per common share $ (0.11) $ (0.11)
Weighted average basic common shares outstanding 38,122,928 28,553,307